Clarity Pharmaceuticals

About

Clarity Pharmaceuticals develops and commercializes PET radiopharmaceuticals and copper-radioisotope theranostics (SARTATE), provides PET-based companion diagnostics and radio‑immunotherapeutics, and offers imaging services for drug development.

Mission

Clarity Pharmaceuticals develops radiopharmaceutical therapies and diagnostic imaging technologies, notably SARTATE™, a radiobiological product that identifies and kills cancerous cells in a localized manner. The company is pioneering the world’s first use of copper radioisotopes for diagnosis, dosimetry and treatment of cancer and completed a first-in-human trial prior to this raise. Results from that trial were slated for presentation at the Society of Nuclear Medicine and Molecular Imaging annual meeting. Proceeds from the current raise will fund a Phase IIa trial of SARTATE™ in neuroendocrine tumours and accelerate trials in neuroblastoma and other difficult-to-treat cancers. Clarity also runs internal programs around radio-immunotherapeutics and PET-based companion diagnostics and emphasises personalised-medicine approaches. The company was founded in 2010, is Sydney-based, and has licensed technology from ANSTO and the University of Melbourne. Clarity Pharmaceuticals commercialises PET radiopharmaceuticals and medical imaging technology licensed from ANSTO and the University of Melbourne, offering services in theranostics, companion diagnostics and internal research on PET-based companion diagnostics and radio-immunotherapeutics. Its pharmaceutical tagging and tracking imaging tools are used by Australian and international pharmaceutical companies during drug development and testing. The company plans to expand international operations in the US, Europe and Asia and to develop personalised medicine applications for its imaging platform. The latest $1.1 million round is intended to advance personalised medicine work and to ramp up existing services and products in local and international markets. Clarity was founded in 2010 by Dr Matt Harris and operates from ATP Innovations in Sydney with access to nuclear medicine infrastructure and researchers. To date the company has raised a total of $3.5 million, including grants from Commercialisation Australia.

Quick Facts